Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Expenses:
Consulting (Note 11)	$ 16,000	$ 45,000	$ 77,250	$ 135,000
Research and development (Note 10)	1,455	4,624	6,186	93,561
Selling, general and administrative (Notes 9 and 11)	51,596	79,049	144,835	200,696
Stock-based compensation (Notes 7 and 11)	290	14,923	5,969	75,936
Loss from operations	(69,341)	(143,596)	(234,240)	(505,193)
Interest income	198	3,089	2,310	9,375
Net loss	(69,143)	(140,507)	(231,930)	(495,818)
Other comprehensive loss
Currency translation differences	(577)	(1,878)	(1,008)	(1,742)
Total comprehensive loss	$ (69,720)	$ (142,385)	$ (232,938)	$ (497,560)
Net loss per share - basic and diluted (in dollars per share)	$ (0)	$ (0)	$ (0)	$ (0.01)
Weighted average number of common shares outstanding – basic and diluted (in shares)	91,422,569	91,422,569	91,422,569	91,422,569